EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte Studie

Early and Late Outcomes With the Absorb Bioresorbable Vascular Scaffold

David A Power, Anton Camaj, Dean J Kereiakes, Stephen G Ellis, Runlin Gao, Takeshi Kimura, Ziad A Ali, Kelly A Stockelman, Ovidiu Dressler, Yoshinobu Onuma, Patrick W Serruys, Gregg W Stone und 1 weitere

JACC: Cardiovascular Interventions · 2025-01 · 18 (1) · 1-11

DOI: 10.1016/j.jcin.2024.08.050 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2025-01. Verfasst von David A Power und 12 weiteren Autor:innen. Beteiligte Einrichtung: Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Absorbable Implants, Cardiovascular Agents, Coronary Artery Disease, Drug-Eluting Stents. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Abbott Vascular.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The risk-benefit ratio of the Absorb bioresorbable vascular scaffold (BVS) may vary before and after 3 years, the time point of complete bioresorption of the poly-L-lactic acid scaffold. OBJECTIVES: The aim of this study was to determine the time-varying outcomes of the Absorb BVS compared with cobalt-chromium everolimus-eluting stents (EES) from a large individual-patient-data pooled analysis of randomized trials. METHODS: The individual patient data from 5 trials that randomized 5,988 patients undergoing percutaneous coronary intervention to the Absorb BVS vs EES with 5-year follow-up were pooled. The primary effectiveness and safety endpoints were target lesion failure (TLF) (cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization) and device thrombosis (DT). RESULTS: Between 0 and 5 years, TLF occurred in 15.9% BVS patients vs 13.1% EES patients (HR: 1.25; 95% CI: 1.08-1.43; P = 0.002), and DT occurred in 2.2% vs 1.0%, respectively (HR: 2.38; 95% CI: 1.49-3.79; P = 0.0002). Between 0 and 3 years, TLF occurred in 12.4% BVS patients vs 9.3% EES patients (HR: 1.35; 95% CI: 1.15-1.59; P = 0.0002), and DT occurred in 2.0% vs 0.6%, respectively (HR: 3.58; 95% CI: 2.01-6.36; P < 0.0001). Between 3 and 5 years, TLF occurred in 4.5% BVS patients vs 4.7% EES patients (HR: 0.99; 95% CI: 0.76-1.27; P = 0.91), and DT occurred in 0.2% vs 0.4%, respectively (HR: 0.49; 95% CI: 0.18-1.38; P = 0.17). By spline analysis, the TLF hazard by 5 years was lower with BVS than EES. CONCLUSIONS: Compared with EES treatment, BVS increased TLF and DT rates through 5-year follow-up. However, the period of excess risk for the first-generation Absorb BVS ended at 3 years, when poly-L-lactic acid bioresorption is complete. Thereafter event rates were comparable or lower with BVS. (ABSORB II Randomized Controlled Trial, NCT01425281; A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold [Absorb™ BVS] System in Chinese Population - ABSORB CHINA Randomized Controlled Trial [ABSORB CHINA], NCT01923740; AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 [Absorb™ BVS] in Japanese Population [ABSORB JAPAN], NCT01844284; ABSORB III Randomized Controlled Trial [ABSORB III], NCT01751906; Absorb IV Randomized Controlled Trial, NCT02173379).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Absorbable ImplantsCardiovascular AgentsCoronary Artery DiseaseDrug-Eluting StentsEverolimusPercutaneous Coronary InterventionAgedFemaleHumansMaleMiddle AgedChromium AlloysCoronary ThrombosisMyocardial InfarctionPolyestersProsthesis DesignRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsTime FactorsTreatment Outcome

Stichwörter der Autor:innen

bioresorbable vascular scaffoldscoronary artery diseasedrug-eluting stent(s)percutaneous coronary intervention

Substanzen

Cardiovascular AgentsChromium AlloysEverolimuspoly(lactide)Polyesters

Autor:innen und Institutionen

  • Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • The Christ Hospital, Heart and Vascular Center, Lindner Research Center, Cincinnati, Ohio.
  • Cleveland Clinic, Cleveland, Ohio, USA.
  • Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China.
  • Kyoto University Hospital, Kyoto, Japan.
  • St. Francis Hospital, Roslyn, New York, USA; Cardiovascular Research Foundation, New York, New York.

Förderung

  • Abbott Vascular

Zitieren

APA

Power, D. A., Camaj, A., Kereiakes, D. J., Ellis, S. G., Gao, R., Kimura, T., Ali, Z. A., Stockelman, K. A., Dressler, O., Onuma, Y., Serruys, P. W., Stone, G. W., & ABSORB Investigators (2025). Early and Late Outcomes With the Absorb Bioresorbable Vascular Scaffold. JACC: Cardiovascular Interventions, 18(1), 1-11. https://doi.org/10.1016/j.jcin.2024.08.050

Vancouver

Power DA, Camaj A, Kereiakes DJ, Ellis SG, Gao R, Kimura T, et al. Early and Late Outcomes With the Absorb Bioresorbable Vascular Scaffold. JACC: Cardiovascular Interventions. 2025;18(1):1-11. doi:10.1016/j.jcin.2024.08.050

BibTeX
@article{Power2025,
  author = {Power, David A and Camaj, Anton and Kereiakes, Dean J and Ellis, Stephen G and Gao, Runlin and Kimura, Takeshi and Ali, Ziad A and Stockelman, Kelly A and Dressler, Ovidiu and Onuma, Yoshinobu and Serruys, Patrick W and Stone, Gregg W and ABSORB Investigators, ABSORB Investigators},
  title = {Early and Late Outcomes With the Absorb Bioresorbable Vascular Scaffold},
  journal = {JACC: Cardiovascular Interventions},
  year = {2025},
  volume = {18},
  number = {1},
  pages = {1--11},
  doi = {10.1016/j.jcin.2024.08.050}
}
Kostenlos starten →